Auf dem Laufenden bleiben
E-Mail-Adresse hinterlassen, um über neue Funktionen von Erikonomie informiert zu werden. Kein Tracking, jederzeit abbestellbar.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Stand: gerade eben aktualisiert
Erikonomie stellt ausschließlich allgemeine, automatisiert berechnete Informationen zu öffentlich verfügbaren Finanzkennzahlen bereit. Dies ist keine Anlageberatung, keine Anlagevermittlung und keine Kauf- oder Verkaufsempfehlung. Alle Angaben ohne Gewähr. Investitionsentscheidungen triffst du eigenverantwortlich.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG erreicht aktuell einen Erikonomie-Score von 62 von 100 Punkten – eine automatisiert berechnete, rein deskriptive Kennzahl aus Profitabilität, Bewertung, finanzieller Gesundheit, Dividende und weiteren Bereichen.
Novartis AG wird von Erikonomie dem Sektor „Gesundheitswesen" zugeordnet.
Die aktuelle Dividendenrendite von Novartis AG liegt bei rund 3.0 %. Nach den bei Erikonomie verfügbaren Daten wurde die Dividende seit 3 Jahren in Folge nicht gekürzt.
KGV 30.39 liegt 22.3 % unter dem Sektor-Median (39.13). Rein deskriptiver KGV-Vergleich, keine Kauf- oder Verkaufsempfehlung.
Der Kurs von Novartis AG ist in den letzten rund 12 Monaten um 27.4 % gestiegen.
Nein. Erikonomie liefert ausschließlich automatisiert berechnete, allgemeine Informationen zu öffentlich verfügbaren Finanzkennzahlen – keine Kauf- oder Verkaufsempfehlung und keine individuelle Anlageberatung. Der Erikonomie-Score und alle weiteren Kennzahlen sind rein deskriptiv.
